XML 32 R22.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
Schedule of estimated useful lives of property, plant and equipment | The Company's property, plant, and equipment primarily consist of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives: ​
​ | ​ | ​
Production equipment |  | 3 to 13 years
Office furniture and equipment |  | 3 to 10 years
Buildings |  | 39 years
Building improvements |  | 15 years
Schedule of significant customers | The following table reflects our significant customers for the three-month and six-month periods ended June 30, 2024 and 2023: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | ​ | Three Months Ended | ​ | ​ | Six Months Ended | ​ | ​ | Six Months Ended | ​
​ |  | June 30, 2024 |  | ​ | June 30, 2023 |  | ​ | June 30, 2024 |  | ​ | June 30, 2023 | ​
Number of significant customers |  | ​ | 4 |  | ​ | ​ | 3 |  | ​ | ​ | 3 |  | ​ | ​ | 3 |
Aggregate dollar amount of net sales to significant customers | ​ | $ | 3.8 | million | ​ | ​ | $ | 4.4 | million | ​ | ​ | $ | 7.3 | million | ​ | ​ | $ | 10.2 | million | ​
Percentage of net sales to significant customers | ​ | ​ | 63.0% | ​ | ​ | ​ | 55.0% | ​ | ​ | ​ | 53.6% | ​ | ​ | ​ | 53.9% | ​
​
Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized | Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended June 30, 2024:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 4,631,773 | ​ | ​ | 333,389 | ​ | ​ | 42,561 | ​ | ​ | 5,848 | ​ | $ | 5,013,571
North and South America sales (excluding U.S.) | ​ |  | 601,000 | ​ |  | — | ​ |  | 59,040 | ​ |  | 6,240 | ​ |  | 666,280
Other international sales | ​ |  | 256,133 | ​ |  | 400 | ​ |  | 87,680 | ​ |  | 5,300 | ​ |  | 349,513
Total | ​ | $ | 5,488,906 | ​ | $ | 333,789 | ​ | $ | 189,281 | ​ | $ | 17,388 | ​ | $ | 6,029,364
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the three months ended June 30, 2023:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 5,780,080 | ​ | $ | 346,297 | ​ | $ | 1,165,634 | ​ | $ | 8,665 | ​ | ​ | 7,300,676
North and South America sales (excluding U.S.) | ​ |  | 210,232 | ​ |  | — | ​ |  | — | ​ |  | — | ​ | ​ | 210,232
Other international sales | ​ |  | 366,312 | ​ |  | 1,748 | ​ |  | 87,612 | ​ |  | 4,700 | ​ | ​ | 460,372
Total | ​ | $ | 6,356,624 | ​ | $ | 348,045 | ​ | $ | 1,253,246 | ​ | $ | 13,365 | ​ | $ | 7,971,280
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended June 30, 2024:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | ​
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | ​ | Total
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | ​ | Revenue
U.S. sales | ​ | $ | 10,185,082 | ​ | ​ | 700,998 | ​ | ​ | 755,432 | ​ | ​ | 13,226 | ​ | $ | 11,654,738
North and South America sales (excluding U.S.) | ​ |  | 755,537 | ​ | ​ | 96 | ​ | ​ | 59,040 | ​ | ​ | 6,240 | ​ |  | 820,913
Other international revenue | ​ |  | 828,612 | ​ | ​ | 143,860 | ​ | ​ | 174,704 | ​ | ​ | 5,900 | ​ |  | 1,153,076
Total | ​ | $ | 11,769,231 | ​ | $ | 844,954 | ​ | $ | 989,176 | ​ | $ | 25,366 | ​ | $ | 13,628,727
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the six months ended June 30, 2023:
​ |  | ​ | ​ |  | Blood |  | ​ | ​ |  | ​ | ​ |  | Total
​ | ​ | ​ | ​ | ​ | Collection | ​ | EasyPoint® | ​ | Other | ​ | Product
Geographic Segment | ​ | Syringes | ​ | Products | ​ | Needles | ​ | Products | ​ | Sales
U.S. sales | ​ | $ | 10,583,166 | ​ | $ | 744,673 | ​ | $ | 1,378,121 | ​ | $ | 18,164 | ​ | $ | 12,724,124
North and South America sales (excluding U.S.) | ​ |  | 4,771,512 | ​ |  | — | ​ |  | — | ​ |  | 212,040 | ​ |  | 4,983,552
Other international sales | ​ |  | 871,854 | ​ |  | 213,948 | ​ |  | 174,204 | ​ |  | 4,700 | ​ |  | 1,264,706
Total | ​ | $ | 16,226,532 | ​ | $ | 958,621 | ​ | $ | 1,552,325 | ​ | $ | 234,904 | ​ | $ | 18,972,382
​
Schedule of diluted EPS under the treasury stock method | The calculation of diluted EPS under the treasury stock method included the following shares in the three and six month periods ending June 30, 2024 and 2023:
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Six Months Ended | ​ | Six Months Ended
​ |  | June 30, 2024 |  | June 20, 2023 | ​ | June 30, 2024 |  | June 30, 2023
Common stock underlying issued and outstanding stock options | ​ | 1,524 |  | 16,033 | ​ | 5,007 |  | 22,041
​ | ​ | 1,524 |  | 16,033 | ​ | 5,007 |  | 22,041
Schedule of earnings per share | The potential dilution, if any, is shown on the following schedule: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Three Months Ended | ​ | Six Months Ended | ​ | Six Months Ended | ​
​ |  | June 30, 2024 |  | June 30, 2023 |  | June 30, 2024 |  | June 30, 2023 | ​
Net loss | ​ | $ | (14,164,640) | ​ | $ | (3,868,568) | ​ | $ | (13,735,256) | ​ | $ | (2,877,596) | ​
Preferred stock dividend requirements | ​ |  | (57,611) | ​ |  | (58,111) | ​ |  | (115,222) | ​ |  | (116,222) | ​
Loss applicable to common shareholders | ​ | $ | (14,222,251) | ​ | $ | (3,926,679) | ​ | $ | (13,850,478) | ​ | $ | (2,993,818) | ​
Average common shares outstanding | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​ |  | 29,937,159 | ​
Average common and common equivalent shares outstanding — diluted | ​ |  | 29,937,159 | ​ |  | 30,169,604 | ​ |  | 29,937,159 | ​ |  | 30,169,604 | ​
Basic loss per share | ​ | $ | (0.48) | ​ | $ | (0.13) | ​ | $ | (0.46) | ​ | $ | (0.10) | ​
Diluted loss per share | ​ | $ | (0.48) | ​ | $ | (0.13) | ​ | $ | (0.46) | ​ | $ | (0.10) | ​
​

X
- Definition Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. + References No definition available. + Details
Name: | rvp_UsefulLifeOfPropertyPlantAndEquipmentTableTextBlock
Namespace Prefix: | rvp_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration